Extension Trial Data Shows Cladribine Benefits Persist in RRMS Patients
The beneficial effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated in a 120-week extension trial
The beneficial effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated in a 120-week extension trial
Ozanimod (RPC1063), an oral selective S1P receptor modulator currently in development, has shown efficacy in reducing relapse rates in relapsing multiple sclerosis.
For patients with relapsing-remitting Multiple Sclerosis (RRMS), concomitant use of selective serotonin-reuptake inhibitors (SSRIs) and fingolimod, does not affect cardiac outcomes related to initiation of fingolimod.
For relapse-remitting MS patients with expanded disability status scale (EDSS) scores of >3, once-daily laquinimod 0.6mg can reduce annualized relapse rates (ARR) and confirmed disability progression (CDP).
No correlation between interferon treatment and antidepressant use was observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported.
An interim 4-year follow-up analysis of fingolimod (Gilenya) found the safety profile of the treatment to be consistent with the results of phase 3 clinical trials, researchers reported at the 68th Annual AAN Meeting.
Natalizumab use has been tied to a reduction in annual relapse rates (AAR) for patients with relapsing-remitting multiple sclerosis (RRMS).
The beneficial effects of oral propionate, an approved food additive, have been demonstrated in humans for the first time, according to a study presented at the 68th Annual AAN Meeting.
Lipoic acid is safe, well tolerated, and offers neuroprotection in patients with secondary progressive multiple sclerosis (MS), results from a “highly promising pilot study” presented at the 68th Annual AAN Meeting have shown.
Patients with relapse-onset multiple sclerosis (MS) who have reached disease steps 3, 4, or 6 should still receive highly effective immunomodulatory therapy to mitigate disability accrual.
Please login or register first to view this content.